Tratamiento de las infecciones graves por Pseudomonas aeruginosa multirresistente

Santos, E Díaz; Jiménez, C. Mora; Río-Carbajo, L. del; Vidal-Cortés, Pablo

doi:10.1016/j.medin.2022.03.015

Cited by 8 publications

(2 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…La elección del antimicrobiano apropiado es de vital importancia en las infecciones graves por P. aeruginosa, conocer a que antimicrobianos son susceptibles con mayor frecuencia las cepas en cada institución, es fundamental para la elección del tratamiento empírico inicial. Existen varios estudios donde se reportan altos porcentajes de resistencia a la mayoría de antimicrobianos probados (Fariñas, 2013;Santos, 2022;Cuesta,2012). Los resultados de nuestro estudio en comparación con los resultados de otros estudios reflejan un comportamiento constante de multirresistencia a los diversos antibióticos.…”

Section: Discussionunclassified

Ciencias de la Salud: Aspectos diagnósticos y preventivos de enfermedades 6

Sousa

2024

View full text Add to dashboard Cite

show abstract

Section: Discussionunclassified

Ciencias de la Salud: Aspectos diagnósticos y preventivos de enfermedades 6

Sousa

2024

View full text Add to dashboard Cite

show abstract

“…First-line treatment for P. aeruginosa infections often includes b-lactam antibiotics in combination with a b-lactamase inhibitor (Diaz Santos et al, 2022). b-lactam antibiotics include penicillins, carbapenems, cephalosporins and monobactams that share a common structure (b-lactam ring) and all target penicillin-binding proteins (PBPs) involved in the synthesis of the peptidoglycan layer (Vollmer and Holtje, 2004).…”

Section: Introductionmentioning

confidence: 99%

Using host-mimicking conditions and a murine cutaneous abscess model to identify synergistic antibiotic combinations effective against Pseudomonas aeruginosa

Lyons,

Wu,

Jin

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Antibiotic drug combination therapy is critical for the successful treatment of infections caused by multidrug resistant pathogens. We investigated the efficacy of β-lactam and β-lactam/β-lactamase inhibitor combinations with other antibiotics, against the hypervirulent, ceftazidime/avibactam resistant Pseudomonas aeruginosa Liverpool epidemic strain (LES) B58. Although minimum inhibitory concentrations in vitro differed by up to eighty-fold between standard and host-mimicking media, combinatorial effects only marginally changed between conditions for some combinations. Effective combinations in vitro were further tested in a chronic, high-density murine infection model. Colistin and azithromycin demonstrated combinatorial effects with ceftazidime and ceftazidime/avibactam both in vitro and in vivo. Conversely, while tobramycin and tigecycline exhibited strong synergy in vitro, this effect was not observed in vivo. Our approach of using host-mimicking conditions and a sophisticated animal model to evaluate drug synergy against bacterial pathogens represents a promising approach. This methodology may offer insights into the prediction of combination therapy outcomes and the identification of potential treatment failures.

show abstract

Conocimiento, colaboración y liderazgo en la batalla contra la infección y aparición de resistencias

Vidal

2023

Medicina Intensiva

View full text Add to dashboard Cite

Tratamiento de las infecciones graves por Pseudomonas aeruginosa multirresistente

Cited by 8 publications

References 87 publications

Ciencias de la Salud: Aspectos diagnósticos y preventivos de enfermedades 6

Ciencias de la Salud: Aspectos diagnósticos y preventivos de enfermedades 6

Using host-mimicking conditions and a murine cutaneous abscess model to identify synergistic antibiotic combinations effective against Pseudomonas aeruginosa

Conocimiento, colaboración y liderazgo en la batalla contra la infección y aparición de resistencias

Contact Info

Product

Resources

About